NCT03134456View on ClinicalTrials.gov

Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 14, 2018

Primary Completion Date

July 8, 2019

Study Completion Date

July 13, 2023

Conditions
Metastatic Non-Small Cell Lung Carcinoma
Interventions
DRUG

Pembrolizumab Injection

Pembrolizumab according to the dosage and administration in Product Information of Keytruda in Korea (2mg/kg) until it is changed to 200mg flat dose.

Trial Locations (1)

135710

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT03134456 - Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX | Biotech Hunter | Biotech Hunter